Document Detail


Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity.
MedLine Citation:
PMID:  20181806     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Disturbed apolipoprotein (apo) C-III metabolism in obese subjects may account for hypertriglyceridemia and increased risk of cardiovascular disease. Atorvastatin and fish oils decrease plasma triglycerides and VLDL concentrations, but the underlying mechanisms are not fully understood. OBJECTIVE: We studied the independent and combined effects of atorvastatin and fish oils on the metabolism of VLDL apo C-III in obese men. DESIGN: We carried out a 6-wk randomized, placebo-controlled, 2 x 2 factorial intervention study of atorvastatin (40 mg/d) and fish oils (4 g/d) on VLDL apo C-III kinetics in the postabsorptive state in 39 abdominally obese men using intravenous administration of d(3)-leucine. VLDL apo C-III isotopic enrichments were measured by using gas chromatography-mass spectrometry with kinetic parameters derived by using a multicompartmental model. RESULTS: Atorvastatin significantly (P < 0.05, main effect) increased the VLDL apo C-III fractional catabolic rate (+0.06 +/- 0.003 pools/d) without significantly altering its production rate (-0.14 +/- 0.18 mg . kg(-1) . d(-1)), accounting for a significant reduction in plasma VLDL apo C-III pool size (-44 +/- 17 mg/L). Fish-oil supplementation significantly decreased plasma triglycerides but did not significantly alter plasma VLDL apo C-III concentrations or kinetic parameters. Combination treatment provided no additional effect on VLDL apo C-III concentrations or kinetics compared with atorvastatin alone. CONCLUSIONS: In obesity, the triglyceride-lowering effect of atorvastatin, but not fish oils, is associated with increased VLDL apo C-III fractional catabolism and hence lower VLDL apo C-III concentrations. Combination treatment provided no significant additional improvement in VLDL apo C-III metabolism compared with atorvastatin alone.
Authors:
Dick C Chan; Minh N Nguyen; Gerald F Watts; Esther Mm Ooi; P Hugh R Barrett
Related Documents :
10750576 - Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein chol...
1643096 - Concentration and distribution of apolipoproteins a-i and e in normolipidemic, whhl and...
2338086 - Apolipoprotein e expression by human-monocyte-derived macrophages. modulation by opsoni...
9252956 - Low fat-monounsaturated rich diets containing high-oleic peanuts improve serum lipoprot...
541756 - Effect of feeding amino acid mixtures on lipid transport from rat liver as measured by ...
24337156 - Exendin-4 is effective against metabolic disorders induced by intrauterine and postnata...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-02-24
Journal Detail:
Title:  The American journal of clinical nutrition     Volume:  91     ISSN:  1938-3207     ISO Abbreviation:  Am. J. Clin. Nutr.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-22     Completed Date:  2010-04-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376027     Medline TA:  Am J Clin Nutr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  900-6     Citation Subset:  AIM; IM    
Affiliation:
Metabolic Research Centre School of MedicinePharmacology Royal Perth Hospital University of Western Australia Perth Western Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anticholesteremic Agents / pharmacology*,  therapeutic use
Apolipoprotein C-III / blood,  metabolism*
Cholesterol, VLDL / blood*
Dietary Supplements
Double-Blind Method
Drug Therapy, Combination
Fatty Acids, Omega-3 / pharmacology*,  therapeutic use
Heptanoic Acids / pharmacology*,  therapeutic use
Humans
Male
Middle Aged
Obesity, Abdominal / blood,  drug therapy*
Pyrroles / pharmacology*,  therapeutic use
Triglycerides / blood*
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Apolipoprotein C-III; 0/Cholesterol, VLDL; 0/Fatty Acids, Omega-3; 0/Heptanoic Acids; 0/Pyrroles; 0/Triglycerides; 110862-48-1/atorvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Perceived Risk of Amputation, Emotions, and Foot Self-care Among Adults With Type 2 Diabetes.
Next Document:  Review of muscle wasting associated with chronic kidney disease.